← Unusual insider activity · Company hub
DGX Quest Diagnostics Inc.
Insider figures are trailing 90 days, open-market Form 4 only. Institutional figures are the latest reported quarter. These windows are not simultaneous.
-$8.3M net selling - trailing 90 days
0 buyers - 3 unique sellers
Historical context: most recent complete month (2026-09) is the 40th percentile of this ticker's monthly net P/S flow over 24 complete months. Lower percentiles are more selling; higher are more buying. P10–P90: -$7.2M to $0.
6 accumulating - 5 trimming - 1 unchanged
12 comparable institutions - Q2 2026
open-market Form 4 only - grants, exercises, tax withholding excluded. ~ derived from SEC-reported shares x price.
Who is responsible
| Insider | Role | Net activity | Rows |
|---|---|---|---|
| PREVOZNIK MICHAEL E | SVP & General Counsel | -~$5.5M | 3 |
| Davis J. E. | CEO and President | -~$2.4M | 1 |
| DELANEY MARK E | SVP & Chief Commercial Officer | -~$0.4M | 1 |
Transactions
| Date | Insider | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| September 1, 2026 | Davis J. E. | CEO and President | S | -10000 | 242.72 | ~$2.4M |
| August 28, 2026 | PREVOZNIK MICHAEL E | SVP & General Counsel | 3 reported sale rows | 22677 | — | ~$5.5M |
| August 28, 2026 | PREVOZNIK MICHAEL E | SVP & General Counsel | S | -430 | 244.5148 | ~$0.1M |
| August 28, 2026 | PREVOZNIK MICHAEL E | SVP & General Counsel | S | -6237 | 243.6275 | ~$1.5M |
| August 28, 2026 | PREVOZNIK MICHAEL E | SVP & General Counsel | S | -16010 | 242.8755 | ~$3.9M |
| July 28, 2026 | DELANEY MARK E | SVP & Chief Commercial Officer | S | -1600 | 235.18 | ~$0.4M |
| June 4, 2026 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | S | -8147 | 200 | ~$1.6M |
| June 1, 2026 | Davis J. E. | CEO and President | S | -10000 | 194.14 | ~$1.9M |
| March 5, 2026 | Doherty Catherine T. | EVP, Regional Businesses | S | -5558 | 206.21 | ~$1.1M |
| March 5, 2026 | PREVOZNIK MICHAEL E | SVP & General Counsel | S | -3878 | 206.21 | ~$0.8M |
| March 5, 2026 | Plewman Patrick | SVP for Diagnostic Services | S | -2855 | 206.21 | ~$0.6M |
| March 4, 2026 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | S | -2628 | 204.86 | ~$0.5M |
| March 3, 2026 | Plewman Patrick | SVP for Diagnostic Services | S | -410 | 207.73 | ~$85K |
| March 3, 2026 | PREVOZNIK MICHAEL E | SVP & General Counsel | S | -526 | 207.73 | ~$0.1M |
| March 3, 2026 | Doherty Catherine T. | EVP, Regional Businesses | S | -632 | 207.73 | ~$0.1M |
| March 2, 2026 | Davis J. E. | CEO and President | S | -10000 | 212.52 | ~$2.1M |
| February 19, 2026 | Plewman Patrick | SVP for Diagnostic Services | S | -958 | 204.83 | ~$0.2M |
| February 19, 2026 | Doherty Catherine T. | EVP, Regional Businesses | S | -1433 | 204.83 | ~$0.3M |
| February 19, 2026 | PREVOZNIK MICHAEL E | SVP & General Counsel | S | -1111 | 204.83 | ~$0.2M |
| February 13, 2026 | Doherty Catherine T. | EVP, Regional Businesses | 5 reported sale rows | 26165 | — | ~$5.4M |
| February 13, 2026 | Doherty Catherine T. | EVP, Regional Businesses | S | -351 | 209.1024 | ~$73K |
| February 13, 2026 | Doherty Catherine T. | EVP, Regional Businesses | S | -1619 | 208.2107 | ~$0.3M |
| February 13, 2026 | Doherty Catherine T. | EVP, Regional Businesses | S | -3500 | 207.0822 | ~$0.7M |
| February 13, 2026 | Doherty Catherine T. | EVP, Regional Businesses | S | -10122 | 206.3706 | ~$2.1M |
| February 13, 2026 | Doherty Catherine T. | EVP, Regional Businesses | S | -10573 | 205.2072 | ~$2.2M |
| February 10, 2026 | Plewman Patrick | SVP for Diagnostic Services | S | -5662 | 204 | ~$1.2M |
| November 25, 2025 | Davis J. E. | CEO and President | 3 reported sale rows | 55093 | — | ~$10.6M |
| November 25, 2025 | Davis J. E. | CEO and President | S | -9342 | 191.5888 | ~$1.8M |
| November 25, 2025 | Davis J. E. | CEO and President | S | -41004 | 192.2715 | ~$7.9M |
| November 25, 2025 | Davis J. E. | CEO and President | S | -4747 | 192.9717 | ~$0.9M |
| November 25, 2025 | Gregg Vicky B | — | S | -1250 | 191.76 | ~$0.2M |
| November 18, 2025 | DELANEY MARK E | SVP & Chief Commercial Officer | S | -7946 | 187.35 | ~$1.5M |
| October 22, 2025 | PFEIFFER GARY M | — | S | -1482 | 182.4 | ~$0.3M |
| September 26, 2025 | PREVOZNIK MICHAEL E | SVP & General Counsel | 2 reported sale rows | 227 | — | ~$43K |
| September 26, 2025 | PREVOZNIK MICHAEL E | SVP & General Counsel | S | -144 | 188.6581 | ~$27K |
| September 26, 2025 | PREVOZNIK MICHAEL E | SVP & General Counsel | S | -83 | 187.2198 | ~$16K |
| September 24, 2025 | PREVOZNIK MICHAEL E | SVP & General Counsel | S | -175 | 187.023 | ~$33K |
| September 23, 2025 | PREVOZNIK MICHAEL E | SVP & General Counsel | S | -28288 | 187.1222 | ~$5.3M |
| August 21, 2025 | Plewman Patrick | SVP for Diagnostic Services | S | -1975 | 185 | ~$0.4M |
| August 19, 2025 | Plewman Patrick | SVP for Diagnostic Services | S | -4532 | 183 | ~$0.8M |
| August 15, 2025 | Plewman Patrick | SVP for Diagnostic Services | S | -1975 | 180 | ~$0.4M |
| August 6, 2025 | Plewman Patrick | SVP for Diagnostic Services | 2 reported sale rows | 5535 | — | ~$1.0M |
| August 6, 2025 | Plewman Patrick | SVP for Diagnostic Services | S | -1975 | 175 | ~$0.3M |
| August 6, 2025 | Plewman Patrick | SVP for Diagnostic Services | S | -3560 | 175 | ~$0.6M |
| July 31, 2025 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | S | -2210 | 170 | ~$0.4M |
| July 30, 2025 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | 2 reported sale rows | 8269 | — | ~$1.4M |
| July 30, 2025 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | S | -3045 | 167.4 | ~$0.5M |
| July 30, 2025 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | S | -5224 | 167.4 | ~$0.9M |
| May 13, 2025 | DELANEY MARK E | SVP & Chief Commercial Officer | S | -874 | 175.31 | ~$0.2M |
| May 12, 2025 | DELANEY MARK E | SVP & Chief Commercial Officer | S | -874 | 175.72 | ~$0.2M |
| April 2, 2025 | Davis J. E. | CEO and President | 15 reported sale rows | 39191 | — | ~$6.6M |
| April 2, 2025 | Davis J. E. | CEO and President | S | -4905 | 168.7184 | ~$0.8M |
| April 2, 2025 | Davis J. E. | CEO and President | S | -2764 | 169.5595 | ~$0.5M |
| April 2, 2025 | Davis J. E. | CEO and President | S | -6950 | 167.86 | ~$1.2M |
| April 2, 2025 | Davis J. E. | CEO and President | S | -5900 | 168.6645 | ~$1.0M |
| April 2, 2025 | Davis J. E. | CEO and President | S | -2493 | 169.5692 | ~$0.4M |
| April 2, 2025 | Davis J. E. | CEO and President | S | -750 | 167.8628 | ~$0.1M |
| April 2, 2025 | Davis J. E. | CEO and President | S | -584 | 168.6991 | ~$99K |
| April 2, 2025 | Davis J. E. | CEO and President | S | -267 | 169.5972 | ~$45K |
| April 2, 2025 | Davis J. E. | CEO and President | S | -1493 | 167.8786 | ~$0.3M |
| April 2, 2025 | Davis J. E. | CEO and President | S | -902 | 168.791 | ~$0.2M |
| April 2, 2025 | Davis J. E. | CEO and President | S | -453 | 169.634 | ~$77K |
| April 2, 2025 | Davis J. E. | CEO and President | S | -2366 | 168.0275 | ~$0.4M |
| April 2, 2025 | Davis J. E. | CEO and President | S | -1411 | 168.7555 | ~$0.2M |
| April 2, 2025 | Davis J. E. | CEO and President | S | -704 | 169.6257 | ~$0.1M |
| April 2, 2025 | Davis J. E. | CEO and President | S | -7249 | 167.8638 | ~$1.2M |
| April 2, 2025 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | S | -2555 | 170 | ~$0.4M |
| March 17, 2025 | PREVOZNIK MICHAEL E | SVP & General Counsel | S | -4643 | 170 | ~$0.8M |
| March 5, 2025 | Doherty Catherine T. | EVP, Regional Businesses | S | -5370 | 174.13 | ~$0.9M |
| March 4, 2025 | PREVOZNIK MICHAEL E | SVP & General Counsel | S | -592 | 175.79 | ~$0.1M |
| March 4, 2025 | Doherty Catherine T. | EVP, Regional Businesses | S | -716 | 175.79 | ~$0.1M |
| February 27, 2025 | PREVOZNIK MICHAEL E | SVP & General Counsel | S | -528 | 172.61 | ~$91K |
| February 27, 2025 | Doherty Catherine T. | EVP, Regional Businesses | S | -824 | 172.61 | ~$0.1M |
| February 20, 2025 | PREVOZNIK MICHAEL E | SVP & General Counsel | S | -604 | 170.99 | ~$0.1M |
| February 20, 2025 | Doherty Catherine T. | EVP, Regional Businesses | S | -899 | 170.99 | ~$0.2M |
| February 19, 2025 | Doherty Catherine T. | EVP, Regional Businesses | S | -535 | 169.71 | ~$91K |
| February 19, 2025 | Plewman Patrick | SVP for Diagnostic Services | S | -320 | 169.71 | ~$54K |
| February 5, 2025 | Gregg Vicky B | — | S | -1250 | 164.568 | ~$0.2M |
| February 5, 2025 | DELANEY MARK E | SVP & Chief Commercial Officer | S | -403 | 164.3031 | ~$66K |
| November 29, 2024 | PREVOZNIK MICHAEL E | SVP & General Counsel | 2 reported sale rows | 35146 | — | ~$5.7M |
| November 29, 2024 | PREVOZNIK MICHAEL E | SVP & General Counsel | S | -3009 | 162.2588 | ~$0.5M |
| November 29, 2024 | PREVOZNIK MICHAEL E | SVP & General Counsel | S | -32137 | 163.1473 | ~$5.2M |
| November 27, 2024 | Doherty Catherine T. | EVP, Regional Businesses | 2 reported sale rows | 33103 | — | ~$5.4M |
| November 27, 2024 | Doherty Catherine T. | EVP, Regional Businesses | S | -28300 | 163.1346 | ~$4.6M |
| November 27, 2024 | Doherty Catherine T. | EVP, Regional Businesses | S | -4803 | 162.1435 | ~$0.8M |
| November 6, 2024 | DEPPE MICHAEL J | SVP, Corp. Controller & CAO | 6 reported sale rows | 18755 | — | ~$2.9M |
| November 6, 2024 | DEPPE MICHAEL J | SVP, Corp. Controller & CAO | S | -2600 | 152.7115 | ~$0.4M |
| November 6, 2024 | DEPPE MICHAEL J | SVP, Corp. Controller & CAO | S | -4135 | 154.736 | ~$0.6M |
| November 6, 2024 | DEPPE MICHAEL J | SVP, Corp. Controller & CAO | S | -2400 | 153.9829 | ~$0.4M |
| November 6, 2024 | DEPPE MICHAEL J | SVP, Corp. Controller & CAO | S | -2100 | 152.7029 | ~$0.3M |
| November 6, 2024 | DEPPE MICHAEL J | SVP, Corp. Controller & CAO | S | -5189 | 154.7424 | ~$0.8M |
| November 6, 2024 | DEPPE MICHAEL J | SVP, Corp. Controller & CAO | S | -2331 | 154.031 | ~$0.4M |
| October 28, 2024 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | S | -1775 | 156.9156 | ~$0.3M |